BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » iPSC » Page 3

iPSC Market Accelerated by Clinical Studies in Japan, Australia, UK, and U.S.

December 2, 2018 By Cade Hildreth (CEO) 1 Comment

Human Induced Pluripotent Stem Cell hiPSC Derived Tissues

Growth of the iPSC market is supported by an increasing number of clinical studies that are investigating the therapeutic potential of iPSC-derived cell therapy products. Induced pluripotent stem cells (called iPSCs or iPS cells) are a type of stem cell that can become any cell within the human body, giving them enormous potential for use within regenerative medicine. [Read more…]

Filed Under: iPS Cells, Stem Cells Tagged With: iPSC

ORIG3N, Producing Patient-Specific iPS Cells – Interview with Robin Smith, CEO

November 12, 2018 By Cade Hildreth (CEO) Leave a Comment

ORIG3N

ORIG3N ORIG3N, a biotechnology start-up headquartered in Boston, is attracting global attention for several reasons. First, it has created the world’s largest blood cell repository. ORIG3N is using these blood cells to produce patient-specific induced pluripotent stem cells (iPSCs), allowing the cells to be ever-renewing and giving rise to a living database of humanity known as LifeCapsule.

Second, the company has two other business segments, called LifeProfile and LifeSystems. These business units of ORIG3N help people to better understand the links between their genes and how their minds and bodies work.

Third, ORIG3N has identified HLA Superdonor matches for 90% of the U.S. population, positioning it to be custodians of this “first of a kind asset on planet earth.”

[Read more…]

Filed Under: Interviews, iPS Cells Tagged With: genetic testing, interview, iPSC, news, Orig3n

Ncardia and Nanion Technologies Align Forces to Accelerate Drug Discovery & Development

October 1, 2018 By Cade Hildreth (CEO) Leave a Comment

Ncardia, merger of Axiogenesis & Pluriomics

Major news broke in the iPSC sector last week when Ncardia (Cologne, Germany) and Nanion Technologies (Munich, Germany) signed a joint marketing and sales promotion agreement. Under the terms of partnership, customers of the companies will get access to high-performance instrument platforms from Nanion, coupled with Ncardia’s portfolio of hiPSC-derived cardiac cell types and assay services. [Read more…]

Filed Under: iPS Cells, Stem Cell News Tagged With: iPSC, Nanion, Ncardia

What Are Stem Cells Used For

September 26, 2018 By Cade Hildreth (CEO) 1 Comment

Feature | What Are Stem Cells Used For

What are stem cells used for? There are many potential uses for stem cells, from the treatment of cancer to chronic conditions, acute injuries and more. Scientists continue to perform research on stem cells to maximize their therapeutic benefits and possible contributions to the medical industry.

In this article:

  • Why Are Stem Cells Important?
  • What Are Stem Cells Used For in Medicine?
  • What Are Stem Cells Used For in the Body?
  • Why Are Stem Cells Valuable in Research?

What Are Stem Cells Used For? | Some FAQs Answered

While stem cells are important for treating people with major health issues, they are also advancing new frontiers in healthcare. [Read more…]

Filed Under: iPS Cells, Stem Cells Tagged With: cell therapy, iPSC

Dr. Paul Wotton on the Future of Cynata Therapeutics’ Novel iPSC-Derived MSCs

July 10, 2018 By Cade Hildreth (CEO) Leave a Comment

Dr. Paul Wotton

This is an interview with Dr. Paul Wotton, who joined Cynata Therapeutics Board of Directors in June, 2016.  Dr. Wotton was previously President and CEO of Ocata Therapeutics, Inc. (NASDAQ: OCAT) joining the company in July 2014 and managing it through an all-cash take-over by Astellas Pharma valued at $379 million.  [Read more…]

Filed Under: Interviews, iPS Cells, MSCs Tagged With: clinical trial, Cymerus, cynata therapeutics, iPSC, MSC, Paul Wotton

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 15
  • Next Page »

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.